- |||||||||| cyclophosphamide / Generic mfg., epirubicin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Journal: Neoadjuvant chemotherapy for primary invasive ductal carcinoma of the nipple: A case report. (Pubmed Central) - Sep 5, 2024 Changes in the nipple should be treated cautiously and a pathological biopsy should be performed in a timely manner. Breast cancer occurring in the nipple can be treated with reference to the same type of common breast cancer, and neoadjuvant chemotherapy can also be performed first if neoadjuvant chemotherapy is indicated.
- |||||||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Case report: outcome of anlotinib treatment in breast cancer patient with brain metastases. (Pubmed Central) - Sep 3, 2024 After the standard first-line treatment including albumin-bound paclitaxel, trastuzumab and pertuzumab, and a second-line treatment involving pyrotinib, capecitabine, and radiotherapy did not produce the desired results, the patient was then administered anlotinib in combination with pyrotinib and letrozole as a third-line treatment, which led to a partial response (PR). The findings suggest that anti-angiogenic therapy, specifically anlotinib, could be regarded as a promising therapeutic option for BC patients with BM.
- |||||||||| Xermelo (telotristat etiprate) / Ipsen, Lexicon Pharma, TerSera Therap
Preclinical, Journal, PD(L)-1 Biomarker: Telotristat ethyl, a tryptophan hydroxylase inhibitor, enhances antitumor efficacy of standard chemotherapy in preclinical cholangiocarcinoma models. (Pubmed Central) - Sep 3, 2024 Standard chemotherapy regimens for CCA, gemcitabine plus cisplatin (GemCis) or its recently approved combination with durvalumab demonstrate dismal clinical activity, yielding a median survival of 12-14?months...Nab-paclitaxel (NPT) significantly enhanced animal survival (60%), surpassing the marginal effects of TE (11%) or GemCis (9%) in peritoneal dissemination xenografts...Furthermore, TE treatment consistently decreased serotonin levels in all tumours under all therapeutic conditions. This investigation decisively demonstrated the antitumor efficacy of TE across a spectrum of CCA preclinical models, suggesting that combination therapies involving TE, particularly for patients exhibiting serotonin overexpression, hold the promise of improving clinical CCA therapy.
- |||||||||| albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Journal: Outcomes After Multimodality Treatment of Pancreatic Cancer in an Unselected Single-Center Cohort. (Pubmed Central) - Sep 2, 2024 Among the 287 patients treated with systemic therapy only, combination chemotherapy was independently associated with longer mOS (11.6 months) as compared to gemcitabine-monotherapy (6.8 months)...In locally advanced PDAC, dRT was associated with longer survival as compared to systemic therapy only. Concerning first-line systemic therapy, our results support the use of combination chemotherapy over single-agent therapy.
- |||||||||| albumin-bound paclitaxel / Generic mfg.
Journal: Functionalizing Sgc8-Paclitaxel Conjugates with F-Base Modifications: Targeted Drug Delivery with Optimized Cardiac Safety. (Pubmed Central) - Sep 2, 2024 Autophagy pathway analysis showed no discernible differences in Sgc8-F23-PTX-treated cardiomyocytes compared with controls, in contrast to the increased autophagy with nanoparticle albumin-bound-paclitaxel (Nab-PTX)...These findings suggest the safety and efficacy of F-base-modified Sgc8 aptamers for targeted drug delivery, holding potential clinical applications. Further research is warranted for clinical translation and exploration of other drug carriers.
- |||||||||| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, AiRuiKa (camrelizumab) / HLB Bio Group
Biomarker, P2 data, Retrospective data, Journal, Tumor microenvironment, PD(L)-1 Biomarker, IO biomarker, Metastases: Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study. (Pubmed Central) - Sep 1, 2024 P1/2 Regular monitoring of skin, blood tests, and urinalysis are necessary, and the possibility of irAE IgA vasculitis should be considered in cases of purpura and AKI during treatment with immune checkpoint inhibitors. The NCIRPs model that was developed and validated using treatment-na
- |||||||||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal, BRCA Biomarker, PARP Biomarker: Germline BRCA1-Mutated Synchronous and Metachronous Pancreatic Acinar Cell Carcinoma With Long-Term Survival. (Pubmed Central) - Aug 27, 2024 Considering that PACC is likely to have BRCA1/2 mutations responsible for HBOC, we need to be aware of the possible presence of multifocal and/or metachronous tumors in patients with PACC. Additionally, patients with PACC should undergo genetic examinations, which would be beneficial in determining treatment strategies and health care for blood relatives.
- |||||||||| albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Journal, Stroma: Research status of the tumor stroma ratio in prognosis and treatment of pancreatic cancer (Pubmed Central) - Aug 26, 2024 Integration of artificial intelligence deep learning models into traditional pathological and imaging assessments facilitates precise evaluation of the TSR. It can also enable stratification and precision treatment of pancreatic cancer patients based on this index.
- |||||||||| Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Review, Journal: Jejunal sarcomatoid carcinoma: A case report and review of literature. (Pubmed Central) - Aug 22, 2024 Although taxane-induced macular edema is reversible, slower anticancer drug discontinuation worsened VA, highlighting the need for regular ophthalmologic evaluation during treatments. This case suggests that chemotherapy, immunotherapy, plus targeted therapy may represent an optimal treatment for intestinal SCA, meriting further investigation.
- |||||||||| Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
Trial completion, Combination therapy, Metastases: AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer (clinicaltrials.gov) - Aug 21, 2024 P1, N=76, Completed, Initiation date: Mar 2024 --> Sep 2024 Active, not recruiting --> Completed
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: The Efficiency and Safety of Triple-Drug Combination of Albumin-Bound Paclitaxel, Anlotinib and PD-1/L1 Inhibitors in the 2nd or Above Line of Advanced NSCLC: A Retrospective Cohort Study. (Pubmed Central) - Aug 13, 2024 Our study displayed that triple-drug combination of nab-ptx, anlotinib and PD-1/L1 inhibitors showed promising efficiency and tolerated cytotoxicity in the 2nd or above line treatment of advanced NSCLC, indicating the potential of such regimen as an important option for second-line treatment of advanced NSCLC. However, due to limitations in patient numbers, its actual clinical value awaits further research confirmation.
- |||||||||| gemcitabine / Generic mfg.
Clinical, Retrospective data, Review, Journal, Combination therapy, Monotherapy, Metastases: Efficacy of first-line combination therapies versus gemcitabine monotherapy for advanced pancreatic cancer: a systematic review and network meta-analysis. (Pubmed Central) - Aug 8, 2024 The analysis revealed that gemcitabine+nab-paclitaxel (GA), GA with platinum and fluorouracil (GA+Plat+FU), gemcitabine with fluorouracil (G+FU), G+Plt+FU, and FOLFIRINOX were associated with superior OS and PFS compared to gemcitabine monotherapy...These findings support the use of gemcitabine-based or fluorouracil-based triplet or quadruplet regimens for better survival outcomes in patients with advanced pancreatic cancer. Further research is warranted to explore the potential benefits of adding chemotherapy agents, such as fluorouracil, to the GA doublet regimen.
- |||||||||| pegylated liposomal doxorubicin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Review, Journal: Chemoradiotherapy and nanomedicine: Drug mechanisms and delivery systems. (Pubmed Central) - Aug 7, 2024 Though many challenges remain, the ongoing progress evidences a promising future for both nanomedicine and chemoradiotherapy. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery > Nanomedicine for Cardiovascular Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies.
- |||||||||| gemcitabine / Generic mfg.
Journal: Preoperative chemotherapy with Gemcitabine for pancreatic cancer causes zinc deficiency. (Pubmed Central) - Aug 5, 2024 The preoperative chemotherapy consistently reduced the serum zinc concentrations in the PC patients, regardless of their regimen such as GEM + S1 and GEM + nab-PTX. Monitoring the serum zinc concentration and appropriate zinc supplementation may be essential for PC patients undergoing preoperative chemotherapy and pancreatectomy.
|